HKSE:01530 (China)
Â
Shs Unitary 144A/Reg S
HK$
5.83
(+1.75%)
Apr 24
Business Description
3SBio Inc
NAICS : 325412
SIC : 2834
ISIN : KYG8875G1029
Share Class Description:
HKSE:01530: Shs Unitary 144A/Reg SCompare
Compare
Traded in other countries / regions
01530.Hong Kong83B.GermanyTRSBF.USA IPO Date
2015-06-11Description
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.24 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.35 | |||||
| Debt-to-EBITDA | 2.05 | |||||
| Interest Coverage | 11.63 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.25 | |||||
| Beneish M-Score | -2.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.5 | |||||
| 3-Year EBITDA Growth Rate | 16.7 | |||||
| 3-Year EPS without NRI Growth Rate | 25 | |||||
| 3-Year FCF Growth Rate | -6.1 | |||||
| 3-Year Book Growth Rate | 12.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12.73 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.68 | |||||
| 9-Day RSI | 48.63 | |||||
| 14-Day RSI | 49.74 | |||||
| 6-1 Month Momentum % | -6.6 | |||||
| 12-1 Month Momentum % | -24.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.47 | |||||
| Quick Ratio | 2.26 | |||||
| Cash Ratio | 1.61 | |||||
| Days Inventory | 232.56 | |||||
| Days Sales Outstanding | 54.66 | |||||
| Days Payable | 76.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.75 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| Forward Dividend Yield % | 4.36 | |||||
| 5-Year Yield-on-Cost % | 1.77 | |||||
| 3-Year Average Share Buyback Ratio | 1.3 | |||||
| Shareholder Yield % | -7.85 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.98 | |||||
| Operating Margin % | 31.59 | |||||
| Net Margin % | 19.82 | |||||
| FCF Margin % | 17.04 | |||||
| ROE % | 11.39 | |||||
| ROA % | 6.71 | |||||
| ROIC % | 12.67 | |||||
| ROC (Joel Greenblatt) % | 39.44 | |||||
| ROCE % | 10.93 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.59 | |||||
| PE Ratio without NRI | 7.37 | |||||
| Price-to-Owner-Earnings | 7.55 | |||||
| PEG Ratio | 0.75 | |||||
| PS Ratio | 1.68 | |||||
| PB Ratio | 0.93 | |||||
| Price-to-Tangible-Book | 1.57 | |||||
| Price-to-Free-Cash-Flow | 10.15 | |||||
| Price-to-Operating-Cash-Flow | 5.77 | |||||
| EV-to-EBIT | 5.26 | |||||
| EV-to-Forward-EBIT | 5.7 | |||||
| EV-to-EBITDA | 4.88 | |||||
| EV-to-Forward-EBITDA | 4.88 | |||||
| EV-to-Revenue | 1.47 | |||||
| EV-to-Forward-Revenue | 1.5 | |||||
| EV-to-FCF | 8.49 | |||||
| Price-to-Projected-FCF | 0.62 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.72 | |||||
| Price-to-Graham-Number | 0.72 | |||||
| Earnings Yield (Greenblatt) % | 19.01 | |||||
| FCF Yield % | 10.24 | |||||
| Forward Rate of Return (Yacktman) % | 15.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
3SBio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 8,548.914 | ||
| EPS (TTM) (HK$) | 0.679 | ||
| Beta | 1.1 | ||
| Volatility % | 34.43 | ||
| 14-Day RSI | 49.74 | ||
| 14-Day ATR (HK$) | 0.233837 | ||
| 20-Day SMA (HK$) | 5.888 | ||
| 12-1 Month Momentum % | -24.33 | ||
| 52-Week Range (HK$) | 4.91 - 8.1 | ||
| Shares Outstanding (Mil) | 2,438.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
3SBio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
3SBio Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
3SBio Inc Frequently Asked Questions
What is 3SBio Inc(HKSE:01530)'s stock price today?
The current price of HKSE:01530 is HK$5.83. The 52 week high of HKSE:01530 is HK$8.10 and 52 week low is HK$4.91.
When is next earnings date of 3SBio Inc(HKSE:01530)?
The next earnings date of 3SBio Inc(HKSE:01530) is 2024-08-23 Est..
Does 3SBio Inc(HKSE:01530) pay dividends? If so, how much?
The Dividend Yield %  of 3SBio Inc(HKSE:01530) is 1.75% (As of Today), Highest Dividend Payout Ratio of 3SBio Inc(HKSE:01530) was 0.23. The lowest was 0.13. And the median was 0.18. The  Forward Dividend Yield % of 3SBio Inc(HKSE:01530) is 4.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers